We were also able to confirm the reliability of using routine FFPE specimens to accurately identify possible targeted pathways that were confirmed relevant in p16-positive versus p16-negative tumors in prior reports, and that could have wider future applicability and inform clinical applications in HNSCC. Here, CDKN2A is linked to head and neck squamous cell carcinoma.